A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

• Status: Recruiting
• Trial end date: 2022-06-10
• Target enrollment: 0
• Participant gender: All

Summary

A Randomized, Placebo-Controlled, Double-blind, Dose Escalation Study to Assess Safety, Efficacy and Pharmacokinetics of GMA301 Injection in Subjects with Pulmonary Arterial Hypertension

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gmax Biopharm LLC.

Criteria

Inclusion Criteria:

Subjects must meet all of the following criteria:

1. Male or female, aged 18 to 75 years inclusive

2. WHO Group 1 PAH related to one of the following conditions:

1. Idiopathic

2. Heritable

3. Drugs or toxins-induced

4. Associated with connective tissue disease

5. Associated with congenital heart disease if subjects underwent surgical correction more than 12 months before Screening

3. Symptoms due to PAH are consistent with WHO functional class II- III;

4. Have not taken endothelin receptor antagonists (ERAs) within 3 months before randomization.

5. Has been taking at least one oral PAH targeted drug that has been approved by local guidelines for at least 3 months before screening with stable dosage and the disease did not worsen during this period.

6. Right heart catheterization (RHC) result meets below criteria when screening.

1. Mean pulmonary arterial pressure (PAP) ≥25 mmHg

2. Pulmonary vascular resistance (PVR) >3 Woods units

3. PA wedge pressure (PAWP) ≤15 mmHg * if a subject has undergone RHC within 3 months before screening, the waveform results will serve as baseline data if they meet entry criteria; and the RHC at Screening will not be repeated.

7. Has a six-minute walk test (6MWT) with distance between 150 to 450 meters at Screening.

8. The dosage of digitalis drugs or L-arginine supplementation must be stable for at least 1 month before Screening, if applicable.

9. No new use of an IV diuretic, cardiotonic or vasoactive drug within 30 days before screening.

10. Both male and female subjects agree to use a medically acceptable method of contraception throughout the entire study period from informed consent signing to 90 days after last dose, if the possibility of conception exists. Medically acceptable methods of contraception include oral, implantable, or injectable contraceptives (starting 2 months before dosing); diaphragm with vaginal spermicide; intrauterine device; condom and partner using vaginal spermicide; and surgical sterilization (6 months after surgery). Women who are surgically sterile or those who are postmenopausal for at least 2 years are not considered to be of childbearing potential. Eligible male and female subjects must agree not to participate in a conception process (i.e. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) during the study and for 90 days after the last dose of study drug.

11. Body weight no less than 40 kg at Screening.

12. Able to understand and willing to sign the Informed Consent Form (ICF) and comply with the study procedures.

Exclusion Criteria:

Subjects who meet any of the following criteria will not be allowed to participate in this study:

1. Diagnosed with WHO Group II, III, IV, V of PH;

2. Using calcium channel blockers when Screening;

3. BP>160/100mmHg at Screening;

4. Systolic BP <90 mmHg at Screening;

5. Pulmonary function test: FEV1<60% of predicted, TLC<60% of predicted, DLCO<60% of predicted;

6. One of the following tests with confirmed pulmonary embolism and/or chronic thrombo-embolic pulmonary hypertension (CTEPH) following initial diagnosis of PAH:

1. Pulmonary ventilation/perfusion scan

2. CT pulmonary angiogram

3. Contrast dye pulmonary angiogram

7. History of sleep apnea.

8. Limited full participation in the 6MWT due to arthritic, neuromuscular, vascular or other diseases unrelated to PAH.

9. History of acute cardiovascular and/or cerebrovascular events within 6 months before screening.

10. Echocardiogram (ECHO) demonstrating at least one of the following:

1. LVEF <50%

2. Mean end-diastolic left ventricular septal and posterior wall thickness of >12 mm

3. Left atrial (LA) area on apical 4 chamber view >20 cm2

4. LA volume by biplane modified Simpsons or area-length methods >55 mL

5. LA volume index >29 mL/m2

6. Significant valvular heart disease including moderate or severe mitral or aortic stenosis with an aortic valve area <1.0 cm2 or mitral valve area <1.5 cm2), greater than moderate aortic or mitral regurgitation, greater than moderate tricuspid or pulmonic stenosis

11. Restrictive, dilated or hypertrophic cardiomyopathy or constrictive pericarditis

12. Using non-oral prostacyclin when screening;

13. Laboratory parameters during screening:

1. Baseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 times the upper limit of normal (ULN) or total bilirubin ≥1.5 times ULN

2. Estimated glomerular filtration rate (eGFR) <60 mL/min by Cockcroft-Gault formula

3. Hemoglobin concentration ≤100 g/L at screening

14. QTc interval by Fridericia's criteria (QTcF) ≥500 msec at screening

15. Malignancy within 5 years before screening visit (with the exception of localized non-metastatic basal cell carcinoma of the skin, non-metastatic carcinoma of the prostate or in-situ carcinoma of the cervix excised with curative results)

16. Alcohol or drug abuse within 1 year before screening

17. A psychiatric, addictive or other disorder that compromises the ability to give informed consent for participating in this study

18. History of organ transplantation

19. Pregnant or nursing females

20. History of HIV

21. Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), or HIV antibody (HIV-ab).

22. Enrolled in another interventional study within 30 days before screening.

23. Any condition that, in the opinion of the investigator, prevents a potential subject from safely participating in the study.